Morgenthaler Hopes to Boost Healthcare Investments with New $850M Fund | GenomeWeb

NEW YORK, Aug. 6 – Venture capital firm Morgenthaler has closed $850 million in a new fund that it will use to double its early-stage investments in the health-care sector, the company said on Monday.

Morgenthaler, with offices in Cleveland and Menlo Park, Calif., has in the past invested in genomics companies including Protogene, which develops DNA microarrays, and Sequana Therapeutics, now a subsidiary of Celera Genomics as a part of Axys Pharmaceuticals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.